The stock of Dermata Therapeutics Inc (NASDAQ: DRMA) has increased by 29.74 when compared to last closing price of 1.58.Despite this, the company has seen a gain of 25.76% in its stock price over the last five trading days. accesswire.com reported 2024-09-05 that SAN DIEGO, CA / ACCESSWIRE / September 5, 2024 / Dermata Therapeutics, Inc. (Nasdaq:DRMA; DRMAW) (“Dermata” or the “Company”), a late-stage biotechnology company focusing on the treatment of medical and aesthetic skin diseases and conditions, today announced it will be presenting at the H.C. Wainwright 26th Annual Global Investment Conference, being held September 9-11, 2024.
Is It Worth Investing in Dermata Therapeutics Inc (NASDAQ: DRMA) Right Now?
The 36-month beta value for DRMA is at 0.76. Analysts have varying views on the stock, with 1 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for DRMA is 1.29M, and currently, shorts hold a 1.75% of that float. The average trading volume for DRMA on September 16, 2024 was 2.19M shares.
DRMA’s Market Performance
DRMA’s stock has seen a 25.76% increase for the week, with a -0.49% drop in the past month and a -19.69% fall in the past quarter. The volatility ratio for the week is 9.91%, and the volatility levels for the past 30 days are at 10.23% for Dermata Therapeutics Inc The simple moving average for the past 20 days is 19.42% for DRMA’s stock, with a -60.40% simple moving average for the past 200 days.
DRMA Trading at 1.43% from the 50-Day Moving Average
After a stumble in the market that brought DRMA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -88.32% of loss for the given period.
Volatility was left at 10.23%, however, over the last 30 days, the volatility rate increased by 9.91%, as shares surge +13.77% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -5.51% lower at present.
During the last 5 trading sessions, DRMA rose by +36.80%, which changed the moving average for the period of 200-days by -75.38% in comparison to the 20-day moving average, which settled at $1.7300. In addition, Dermata Therapeutics Inc saw -77.60% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for DRMA
The total capital return value is set at -3.05. Equity return is now at value -173.01, with -140.74 for asset returns.
Currently, EBITDA for the company is -8.04 million with net debt to EBITDA at 0.49. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.73.
Conclusion
In conclusion, Dermata Therapeutics Inc (DRMA) has had a bad performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
